Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TNG.PA
- Price
- 0.63
- Stock movement down
- -0.01 (-1.25%)
- Company name
- Transgene SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 83.87M
- Ent value
- 116.72M
- Price/Sales
- 19.43
- Price/Book
- 32.42
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -56.46%
- 3 year return
- -34.63%
- 5 year return
- -17.35%
- 10 year return
- -18.01%
Last updated: 2025-04-12
DIVIDENDS
TNG.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 19.43 |
| Price to Book | 32.42 |
| EV to Sales | 27.04 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 132.29M |
| EPS (TTM) | -0.38 |
| FCF per share (TTM) | -0.66 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.32M |
| Gross profit (TTM) | -17.49M |
| Operating income (TTM) | -52.17M |
| Net income (TTM) | -38.81M |
| EPS (TTM) | -0.38 |
| EPS (1y forward) | -0.47 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -405.18% |
| Operating margin (TTM) | -1208.80% |
| Profit margin (TTM) | -899.28% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.32M |
| Net receivables | 2.06M |
| Total current assets | 19.12M |
| Goodwill | 0.00 |
| Intangible assets | 74.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 50.75M |
| Accounts payable | 7.31M |
| Short/Current long term debt | 90.00K |
| Total current liabilities | 12.17M |
| Total liabilities | 48.16M |
| Shareholder's equity | 2.59M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -52.80M |
| Capital expenditures (TTM) | 4.70M |
| Free cash flow (TTM) | -66.99M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -1500.31% |
| Return on Assets | -76.48% |
| Return on Invested Capital | -1449.87% |
| Cash Return on Invested Capital | -2502.41% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.62 |
| Daily high | 0.64 |
| Daily low | 0.62 |
| Daily Volume | 19K |
| All-time high | 98.54 |
| 1y analyst estimate | 2.20 |
| Beta | 0.80 |
| EPS (TTM) | -0.38 |
| Dividend per share | - |
| Ex-div date | 16 Jul 2014 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| TNG.PA | S&P500 | |
| Current price drop from All-time high | -99.36% | -12.89% |
| Highest price drop | -99.42% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -87.40% | -11.07% |
| Avg time to new high | 460 days | 12 days |
| Max time to new high | 6416 days | 1805 days |
COMPANY DETAILS
Marketcap
83.87M
Marketcap category
Small-cap
Description
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Employees
146
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found